Coya Therapeutics To Highlight ALS Data In Poster Presentation At 2026 Annual NEALS Meeting; Co. Currently Conducts ALSTARS Trial, Phase 2/3, Study To Evaluate COYA 302 For ALS Treatment
Coya Therapeutics will present ALS treatment data at a medical conference while conducting a Phase 2/3 trial.· summarised by Stockedin
BenzingaRead at the source
COYA